Ironwood Pharmaceuticals, Inc.
IRWDHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeIronwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and. The company carries a $571.7M market cap, placing it firmly in the small-cap category. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
Market Cap
$571.7M
Beta
0.22
P/E (TTM)
4.49
P/E (Fwd)
2.31
EPS (TTM)
$0.77
EPS (Fwd)
$1.50
ROE
—
ROA
47.0%
Cash
$79.1M
Total Debt
$396.9M
Free CF
$121.8M
52W Change
108.4%
Annual Financials
Cash vs Debt
Where IRWD stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, IRWD finished 8.16% below its 150-day moving average ($3.92) and 10.45% below its 200-day moving average ($4.02). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IRWD overbought or oversold?
At the October 15, 2026 close, IRWD's RSI(14) was 25.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Ironwood Pharmaceuticals, Inc. carries $396.9M in total debt against $79.1M in cash reserves — debt is roughly 5.0x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $121.8M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on assets of 47.0% further supports the picture of efficient asset utilization. Revenue has pulled back from $410.6M (2022) to $296.2M (2025), a 28% decline worth watching.
IRWD's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Ironwood Pharmaceuticals, Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Ironwood Pharmaceuticals, Inc. and its sector.